Market LIVE
Published markets; coverage varies by country
Product profile · United States

COXANTO

 ·  Patent Litigation & Settlement History ↓

IngredientOXAPROZIN
Application typeNDA
Application217927
Product001
Dosage formCAPSULE
RouteORAL
Strength300MG
Approval date2023-10-20
Marketing statusPrescription
Status event—
ApplicantSOLUBIOMIX
Product source

Current GenericRadar decision

Year2000
SelectionCANDIDATE
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2000-04-29
Patent anchor—
Exclusivity anchor2000-04-29
Protection date2000-04-29
First Final ANDA—
Status event—

NO_ADOPTED_POST_ANCHOR_TAIL_IN_CHECKED_SOURCES

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE1992-10-291997-10-29English description not available.YY1997-10-29—Source
SPECIAL_21051997-10-291999-10-29English description not available.YY1999-10-29—Source
NCE*PED1999-10-292000-04-29English description not available.YY2000-04-29—Source

2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (4)
TypeDateRoleBasisSource
REGULATORY_EXCLUSIVITY1997-10-29SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY1999-10-29SCOPE_CONTEXTEnglish description not available.Source
REGULATORY_EXCLUSIVITY2000-04-29CANONICAL_ANCHOREnglish description not available.Source
REGULATORY_STATUS2000-04-29CANONICAL_DECISIONNO_ADOPTED_POST_ANCHOR_TAIL_IN_CHECKED_SOURCESSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.